I suspect the point is that the Telix’s treatment is easier to administer, and also better tolerated by the patients. In addition, there is hope that the overall survival figures for Telix’s treatment (whenever they become available) will actually be significantly better than the alternative (as a previous study seemed to suggest). That’s my take anyway.
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS, page-69
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.58 |
Change
-0.360(1.64%) |
Mkt cap ! $7.252B | |||
| Open | High | Low | Value | Volume |
| $21.88 | $21.88 | $21.56 | $2.089M | 96.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10 | $21.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.58 | 43 | 1 |
View Market Depth
| Last trade - 11.02am 16/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |